Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Multiple Sclerosis Journal |
Vol/bind | 27 |
Udgave nummer | 14 |
Sider (fra-til) | 2254-2266 |
Antal sider | 13 |
ISSN | 1352-4585 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This investigator sponsored study was funded by Sanofi. The funder had no influence on the study design, data analysis, and interpretation.
Publisher Copyright:
© The Author(s), 2021.
ID: 303771863